US Deprescribing Research Network Pilot and Grant Opportunity
Application Deadlines: 1/22/21
The US Deprescribing Research Network funds pilot and exploratory studies, grant planning activities, and small collaboration grants. The goals of these grant programs are to support early-stage research in deprescribing that has high potential to develop into future large projects, to catalyze research in areas that are of particular importance to the field, to support junior investigator development, and to promote collaborations that will lead to future research projects.
- Pilot awards
- Grant planning awards
- Collaboration awards
- Learn about network grantees and their projects
The Letter of Intent deadline has passed, but it is not required. Application deadline is January 22. See details here
Junior Investigator Intensive Program in Deprescribing Research
The US Deprescribing Research Network (USDeN) seeks applicants for its Junior Investigator Intensive Program in Deprescribing Research. The program will create a cohort of emerging leaders who are committed to pursuing research training and collaborative opportunities related to deprescribing.
Applications Due: February 1, 2021
Selected Investigators Notified: Mid-March, 2021
What is deprescribing research and why is it important?
There is increasing recognition that use of some medication, especially as people get older or more ill, can cause more harm than good. Optimizing medication through targeted deprescribing is a vital part of managing chronic conditions, avoiding adverse effects and improving outcomes. The goals of deprescribing include reducing medication burden and maintaining or improving quality of life. Yet, there is a dearth of strong research evidence to guide clinical practice and inform shared clinical decision-making relevant to deprescribing.
What is the Junior Investigator Intensive Program?
The program has 3 main components.
- Scholars will attend a special session at the 2021 US Deprescribing Research Network Annual Meeting (date to be determined) that is focused on career development, networking, and collaborative research opportunities for early-stage investigators interested in deprescribing. *Due to the COVID-19 pandemic this meeting may be held virtually.*
- Scholars will attend monthly virtual “works in progress” meetings and other activities over the year that offer a mix of opportunities to get feedback on your research from colleagues and senior researchers and discussion of collaborative research projects in which scholars can participate (and help lead).
- Scholars will have access to other aspects of the US Deprescribing Research Network such as attendance at webinars, consultations, and a variety of other resources. Scholars will be expected to attend the virtual USDeN Annual Meeting and most of the monthly web-based meetings during the year.
See full details here.
Application Deadline 2/1/21: Hopkins’ Economics of Alzheimer’s Disease & Services (HEADS) Center Pilot Grant
Pilot Proposal Guidelines (Pilot 2021-2022)
Application Deadline: February 1, 2021 11:59 PM (EST)
The HEADS Center stimulates and coalesces population-based research that identifies, quantifies, and addresses economic and care systems challenges posed by Alzheimer’s Disease and Related Dementias (ADRD).
We invite applications for pilot grants related to our two themes:
(1) To identify and quantify the range of care needs of persons with ADRD and the economic consequences of ADRD for patients and families.
(2) To examine how the organization, financing, and delivery of services affects accessibility, affordability, quality, and equity of ADRD care.
We expect to award 4 one-year pilot grants of up to $25,000 per award in the coming 2021-2022 cycle. We are particularly interested in supporting promising post-doctoral fellows and junior faculty, but applicants may be of any rank from Johns Hopkins University and external institutions.
Please see the attached RFA and click on the link to our website below for full details and application instructions.
Applicants will be notified of funding decisions on or around April 1, 2021.